{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:27:53Z","timestamp":1777181273024,"version":"3.51.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/pas.0b013e31826af296","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T10:25:37Z","timestamp":1350383137000},"page":"1724-1728","source":"Crossref","is-referenced-by-count":22,"title":["Venlafaxine-induced Cholestatic Hepatitis"],"prefix":"10.1097","volume":"36","author":[{"given":"Sylvia","family":"Stadlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Portmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Tschopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi M.","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210131","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00003495-199549020-00010","article-title":"Venlafaxine. A review of its pharmacology and therapeutic potential in depression.","volume":"49","author":"Holliday","year":"1995","journal-title":"Drugs"},{"key":"R2-16-20210131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1188\/02.ONF.33-40","article-title":"Venlafaxine for the control of hot flashes: results of a longitudinal continuation study.","volume":"29","author":"Barton","year":"2002","journal-title":"Oncol Nurs Forum"},{"key":"R3-16-20210131","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"key":"R5-16-20210131","doi-asserted-by":"crossref","first-page":"944","DOI":"10.7326\/0003-4819-130-11-199906010-00014","article-title":"Venlafaxine-associated hepatitis.","volume":"130","author":"Horsmans","year":"1999","journal-title":"Ann Intern Med"},{"key":"R6-16-20210131","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1345\/aph.18155","article-title":"Acute liver damage possibly related to sertraline and venlafaxine ingestion.","volume":"33","author":"Kim","year":"1999","journal-title":"Ann Pharmacother"},{"key":"R7-16-20210131","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/0003-4819-132-5-200003070-00016","article-title":"Venlafaxine-associated hepatitis.","volume":"132","author":"Cardona","year":"2000","journal-title":"Ann Intern Med"},{"key":"R8-16-20210131","first-page":"804","article-title":"Acute cytolytic hepatitis after taking venlafaxine.","volume":"26","author":"Maroy","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"R9-16-20210131","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1345\/aph.1D205","article-title":"Low-dose venlafaxine-associated liver toxicity in chronic hepatitis.","volume":"38","author":"Sencan","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R10-16-20210131","first-page":"340","article-title":"Venlafaxine induced hepatitis.","volume":"52","author":"Pradeep","year":"2004","journal-title":"J Assoc Physicans India"},{"key":"R11-16-20210131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1345\/aph.1G339","article-title":"Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms.","volume":"40","author":"Phillips","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R12-16-20210131","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.gastrohep.2008.11.012","article-title":"Venlafaxine-induced cholestatic hepatitis.","volume":"32","author":"Arroyo","year":"2009","journal-title":"Gastroenterol Hepatol"},{"key":"R13-16-20210131","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.transproceed.2009.09.022","article-title":"Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report.","volume":"41","author":"Detry","year":"2009","journal-title":"Transplant Proc"},{"key":"R14-16-20210131","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1665-2681(19)31780-6","article-title":"Venlafaxine-induced hepatotoxicity in a patient with ulcerative colitis.","volume":"8","author":"Yildirim","year":"2009","journal-title":"Ann Hepatol"},{"key":"R15-16-20210131","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"R16-16-20210131","first-page":"435","article-title":"Influence of CYP2D6 activity on the disposition of the antidepressant agent venlafaxine in humans.","volume":"9","author":"Lessard","year":"1999","journal-title":"Pharmacogenetics"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00000478-201211000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:32:14Z","timestamp":1618036334000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201211000-00016"}},"subtitle":["Case Report and Review of Literature"],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0b013e31826af296","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}